Abstract: A structural printed wiring board panel includes a multilayer printed wiring board having opposing, outer faces and interlayer interconnects that route RF, power and control signals. Connection areas are formed in or on at least on one face for connecting the interlayer interconnects and any electrical components. A metallic face sheet is secured onto at least one outer face, adding structural rigidity to the multilayer printed wiring board. A metallic face sheet can have apertures positioned to allow access to connection areas. RF components can be carried by a face sheet and operatively connected to connection areas.

Abstract: The present invention relates to the use of sertindole in the preparation of a pharmaceutical composition for the preventive treatment of suicidal behaviour in human subjects suffering from a psychotic illness such as schizophrenia or schizoaffective psychosis.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: A catheter system is disclosed including an elongated catheter, an elongated balloon carrier and a disposable balloon formed from an expandable and resilent biocompatible material. The balloon has a lumen disposed between a proximal end and a distal end thereof. The proximal end of the carrier and the distal end of the catheter are configured to permit the distal end of the catheter to matingly engage the proximal end of the carrier. The outer diameter of the balloon carrier and the outer diameter of the balloon are configured such that the diameter of the carrier and the diameter of the balloon permit the balloon first to be slideably mounted onto the balloon carrier and second to be slideably moved from the carrier onto the catheter when the proximal end of the carrier is matingly or otherwise suitably engaged with the distal end of the catheter.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof.

Abstract: The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.

Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Abstract: A structural printed wiring board panel includes a multilayer printed wiring board having opposing, outer faces and interlayer interconnects that route RF, power and control signals. Connection areas are formed in or on at least on one face for connecting the interlayer interconnects and any electrical components. A metallic face sheet is secured onto at least one outer face, adding structural rigidity to the multilayer printed wiring board. A metallic face sheet can have apertures positioned to allow access to connection areas. RF components can be carried by a face sheet and operatively connected to connection areas. Antenna elements can be positioned on the same or an opposing face sheet and operatively connected to RF components to form a phased array printed wiring board (PWB) panel.

Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.

Abstract: In general, the invention is directed to a balloon catheter system for intra-luminal or intra-cavity pressure measurements. In accordance with the invention, the balloon catheter system provides a closed fluid charging mechanism to charge and discharge a balloon mounted on the catheter. More particularly, the charging mechanism may include a closed reservoir, a passage, and an actuator that acts to drive fluid out of the reservoir and through the passage. A lumen within a catheter may transport fluid from the passage to charge the balloon. The pressure monitoring catheter system may take pressure measurements when the balloon is charged. Discharging the balloon may include withdrawing the actuator from the charging mechanism, which fills the reservoir with fluid from the balloon. In addition, a seal member may be used in the pressure monitoring catheter system to provide a more sealed environment for holding and transporting fluid.

Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and ?1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

Abstract: A disposable balloon catheter and corresponding catheter system are disclosed. In one embodiment, the catheter system comprises several components, such as: (a) an elongated catheter comprising a first outer diameter, a first proximal end and a first distal end; (b) an elongated balloon carrier having a second proximal end, a second distal end and a second outer diameter, the second proximal end of the carrier and the first distal end of the catheter being configured to permit the first distal end of the catheter to matingly engage the second proximal end of the carrier, the second outer diameter of the balloon carrier being similar to the first outer diameter of the catheter; and (c) a disposable balloon formed from an expandable and resilient biocompatible material, the balloon having a lumen disposed between a third proximal end and a third distal end thereof, the lumen having at least a third inside diameter.